Delivery Order SPE2DB22D1202-SPE2DB25FVGC5
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Nucynta (tapentadol) 50 mg tablets in quantities of 100 units, with a ceiling value of $1,225.04. This firm fixed-price delivery order is scheduled for completion by July 31, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation, reflecting...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Nucynta ER (tapentadol extended-release) 100mg tablets, valued at $6,005.43. This firm fixed-price delivery order, which represents a child contract under a larger vehicle, is scheduled for completion by August 5, 2025, and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. The award was made through open...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Nucynta ER 100 mg tablets (60-count units) valued at $2,944.08 under a firm fixed-price contract. This delivery order represents a child contract issued against AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which carries a $999,999,999.00 ceiling and extends through December 2026. The award was competitively...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 1, 2025, for the supply of Nucynta ER 50 mg tablets (60-count units) valued at $1,194.33. This competitively awarded, firm fixed-price contract is not set-aside and carries an ultimate completion date of August 4, 2025. The order will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Nucynta ER is an opioid pain management medication, reflecting the Defense...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 5, 2025, for the supply of Nucynta ER 200 mg tablets (60-count units) valued at $4,050.39. This firm fixed-price contract, with an ultimate completion date of August 6, 2025, represents a non-set-aside competitive award to support federal pharmaceutical procurement needs. The place of performance is listed as AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $1,367.15 to AmerisourceBergen Drug Corp for the supply of Nucynta ER 150 mg tablets (60-count) on August 5, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and will be performed at the awardee's facility in Conshohocken, Pennsylvania, with an ultimate completion date of August 6, 2025. The order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop...
- The Defense Logistics Agency awarded a delivery order valued at $1,899.74 to AmerisourceBergen Drug Corp for the supply of Nucynta ER 150 mg tablets (60-count units) on August 5, 2025, with an ultimate completion date of August 6, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The order represents a child contract action under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Nucynta ER 200 mg tablets (60-count units) at a ceiling value of $3,670.09. This is a firm fixed-price delivery order with an ultimate completion date of July 28, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. No set-aside designation was used for this competitive award. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order valued at $4,416.12 to AmerisourceBergen Drug Corp for the supply of Nucynta ER 100 mg tablets (60-count units) on August 5, 2025, with completion targeted for August 6, 2025. The contract employs firm fixed pricing with no set-aside designation, indicating competitive award. Performance will be executed from the vendor's Conshohocken, Pennsylvania location, which serves as the company's corporate headquarters and primary distribution...
- The Defense Logistics Agency awarded a $1,837.56 delivery order to AmerisourceBergen Drug Corp on July 29, 2025, for the supply of Nucynta (tapentadol) 50 mg tablets in quantities of 100 units. This is a firm fixed-price delivery order with a completion deadline of July 30, 2025, and represents a child contract under AmerisourceBergen's larger federal contract portfolio. The award carries no set-aside designation, indicating it was competitively awarded. Performance will occur at the vendor's...
- SPE2DB22D1202Indefinite Delivery Contract
- SPE2DB22D1202-SPE2DB25FVGC5Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 31, 2025, for the supply of Nucynta ER 100 mg tablets (60-count packages) valued at $1,975.65. This competitively awarded, firm fixed-price delivery order is scheduled for completion by August 1, 2025, and will be fulfilled from AmerisourceBergen's corporate office located in Conshohocken, Pennsylvania. The contract contains no set-aside designation, reflecting open competition among qualified pharmaceutical suppliers capable of meeting federal medical procurement standards. This delivery order is issued under AmerisourceBergen's Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. As a prime pharmaceutical vendor serving the Defense Health Agency and other federal healthcare systems, AmerisourceBergen fulfills critical medical supply needs across multiple therapeutic domains through competitively awarded delivery orders. Nucynta ER (tapentadol extended-release) is a centrally acting synthetic opioid analgesic used for pain management within military healthcare programs, demonstrating the company's role as a key distributor of controlled pharmaceutical products to support global military medical operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.0k | 7/31/25 |